[go: up one dir, main page]

BRPI0311233B8 - métodos in vitro para triagem de um paciente para carcinoma hepatocelular (hcc), e para diagnosticar hcc em um paciente, bem como método e kit para detectar ou determinar o nível de gpc3 em uma amostra - Google Patents

métodos in vitro para triagem de um paciente para carcinoma hepatocelular (hcc), e para diagnosticar hcc em um paciente, bem como método e kit para detectar ou determinar o nível de gpc3 em uma amostra

Info

Publication number
BRPI0311233B8
BRPI0311233B8 BRPI0311233A BRPI0311233A BRPI0311233B8 BR PI0311233 B8 BRPI0311233 B8 BR PI0311233B8 BR PI0311233 A BRPI0311233 A BR PI0311233A BR PI0311233 A BRPI0311233 A BR PI0311233A BR PI0311233 B8 BRPI0311233 B8 BR PI0311233B8
Authority
BR
Brazil
Prior art keywords
patient
hcc
gpc3
screening
determining
Prior art date
Application number
BRPI0311233A
Other languages
English (en)
Inventor
Filmus Jorge
Capurro Mariana
Original Assignee
Sunnybrook And Womens College Health Sciences Centre
Sunnybrook Health Sciences Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29584393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0311233(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sunnybrook And Womens College Health Sciences Centre, Sunnybrook Health Sciences Ct filed Critical Sunnybrook And Womens College Health Sciences Centre
Publication of BRPI0311233A2 publication Critical patent/BRPI0311233A2/pt
Publication of BRPI0311233B1 publication Critical patent/BRPI0311233B1/pt
Publication of BRPI0311233B8 publication Critical patent/BRPI0311233B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • G01N33/57525—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

diagnóstico de carcinoma hepatocelular a invenção refere-se a um método para triar um paciente para hcc, determinando o nível de glipicano (gpc3) em uma amostra de fluido corporal do paciente. é proporcionado um método adicional para diagnosticar hcc .por meio da detecção de gpc3 em uma amostra de tecido hepático. também são proporcionados anticorpos os quais ligam especificamente ao gpc3.
BRPI0311233A 2002-05-23 2003-05-22 métodos in vitro para triagem de um paciente para carcinoma hepatocelular (hcc), e para diagnosticar hcc em um paciente, bem como método e kit para detectar ou determinar o nível de gpc3 em uma amostra BRPI0311233B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38234002P 2002-05-23 2002-05-23
US60/382,340 2002-05-23
PCT/CA2003/000752 WO2003100429A2 (en) 2002-05-23 2003-05-22 Diagnosis of hepatocellular carcinoma

Publications (3)

Publication Number Publication Date
BRPI0311233A2 BRPI0311233A2 (pt) 2016-06-28
BRPI0311233B1 BRPI0311233B1 (pt) 2019-08-13
BRPI0311233B8 true BRPI0311233B8 (pt) 2021-07-27

Family

ID=29584393

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0311233A BRPI0311233B8 (pt) 2002-05-23 2003-05-22 métodos in vitro para triagem de um paciente para carcinoma hepatocelular (hcc), e para diagnosticar hcc em um paciente, bem como método e kit para detectar ou determinar o nível de gpc3 em uma amostra

Country Status (17)

Country Link
US (1) US7883853B2 (pt)
EP (1) EP1506406B1 (pt)
JP (1) JP4455324B2 (pt)
CN (1) CN100401068C (pt)
AT (1) ATE425461T1 (pt)
AU (1) AU2003229191B2 (pt)
BR (1) BRPI0311233B8 (pt)
CA (1) CA2482881C (pt)
DE (1) DE60326567D1 (pt)
ES (1) ES2324029T3 (pt)
IL (1) IL164848A0 (pt)
MX (1) MXPA04011132A (pt)
NZ (1) NZ536521A (pt)
PT (1) PT1506406E (pt)
RU (1) RU2319969C2 (pt)
WO (1) WO2003100429A2 (pt)
ZA (1) ZA200410077B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002338020A1 (en) * 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
WO2004023145A1 (ja) * 2002-09-04 2004-03-18 Perseus Proteomics Inc. Ｇｐｃ3の検出による癌の診断方法
WO2004022595A1 (ja) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha MRL/lprマウスを用いた抗体の作製
US7303914B2 (en) * 2003-01-30 2007-12-04 Hongyang Wang Monoclonal antibody against human hepatoma and use thereof
WO2005023301A1 (ja) * 2003-09-04 2005-03-17 Chugai Seiyaku Kabushiki Kaisha 胆管癌治療剤および検出薬
WO2005085861A2 (en) * 2004-03-03 2005-09-15 Oridis Biomed Forschungs- Und Entwicklungs Gmbh Nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer
WO2005106485A1 (ja) 2004-04-28 2005-11-10 Perseus Proteomics Inc. 肝癌治療後の再発予測判定薬
CN102702353A (zh) * 2004-07-09 2012-10-03 中外制药株式会社 抗-磷脂酰肌醇蛋白聚糖3抗体
ES2422898T3 (es) 2004-08-24 2013-09-16 Chugai Seiyaku Kabushiki Kaisha Terapia adyuvante con el uso de anticuerpo anti-glipicano 3
EP1813944A4 (en) * 2004-10-05 2009-11-11 Perseus Proteomics Inc DRUG TO MONITOR THE INJURY OF HEPATITIS
AU2005297772B2 (en) 2004-10-26 2011-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody having modified sugar chain
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2007053659A2 (en) * 2005-11-01 2007-05-10 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of screening for hepatocellular carcinoma
KR20110005812A (ko) * 2008-03-17 2011-01-19 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 항-글리피칸-3 항체를 사용하여 간암 세포를 검출하는 방법
CN101393217B (zh) * 2008-09-27 2012-05-30 中国人民解放军第二军医大学 一种原发性肝癌血清标志物的检测试剂盒
JP5439494B2 (ja) * 2008-10-21 2014-03-12 バイエル ヘルスケア エルエルシー 肝細胞癌と関連するシグネチャ遺伝子の同定
KR20100098324A (ko) * 2009-02-27 2010-09-06 포항공과대학교 산학협력단 Ｔｍ７ｓｆ３를 유효성분으로 함유하는 간암 진단용 조성물, 및 항 ｔｍ７ｓｆ３ 항체를 유효성분으로 함유하는 간암 진단 키트, 및 간암 예방 또는 치료용 약학 조성물
JP5704570B2 (ja) 2009-03-05 2015-04-22 独立行政法人産業技術総合研究所 肝内胆管がんの検出、判別方法
CN102180969B (zh) * 2011-01-30 2013-04-10 中国人民解放军军事医学科学院微生物流行病研究所 抗肝癌活性单克隆抗体及其应用
CN102183660A (zh) * 2011-03-09 2011-09-14 倪温慨 检测Glypican-3的时间分辨免疫荧光试剂盒
CN102353791A (zh) * 2011-06-30 2012-02-15 倪润洲 一种分离检测afp亚型的新方法
EP3557260B1 (en) 2012-12-21 2022-05-18 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
WO2014159087A1 (en) * 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Radiolabeled anti-glypican-3 immunoconjugates for immuno-pet imaging of hepatocellular carcinoma
WO2015020242A1 (ko) * 2013-08-06 2015-02-12 Kim Hyun Kee 소 간세포암 및 간경변에 잠재되어 있는 간세포암 진단용 조성물
CN105849562B (zh) 2013-12-24 2019-08-16 中外制药株式会社 可溶性gpc3蛋白质的测定方法
US11760807B2 (en) 2014-05-08 2023-09-19 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy
WO2015179658A2 (en) * 2014-05-22 2015-11-26 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
KR101704533B1 (ko) * 2014-10-13 2017-02-09 경북대학교병원 간암 바이오마커로서의 ＥＲＲγ 및 이의 용도
WO2017002934A1 (ja) 2015-07-01 2017-01-05 中外製薬株式会社 Ｇｐｃ３標的治療剤が有効である患者に投与されるｇｐｃ３標的治療剤
EP3333192B1 (en) * 2015-08-03 2021-05-19 Cafa Therapeutics Limited Antibody against glypican-3 and application thereof
JP6292564B2 (ja) * 2016-03-10 2018-03-14 シスメックス株式会社 肝細胞がん患者の再発リスク予測を補助する方法、装置、コンピュータプログラム製品及びキット
WO2017159699A1 (en) 2016-03-15 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
JP7382922B2 (ja) 2017-09-20 2023-11-17 中外製薬株式会社 Ｐｄ－１系結合アンタゴニストおよびｇｐｃ３標的化剤を使用する併用療法のための投与レジメン
US20250000906A1 (en) 2021-11-16 2025-01-02 Sotio Biotech Inc. Treatment of myxoid/round cell liposarcoma patients
CN114813266B (zh) * 2022-03-15 2025-08-22 中国人民解放军海军军医大学第三附属医院 血液样本中gpc-3复合物的富集、检测方法及应用
WO2024255815A1 (zh) 2023-06-16 2024-12-19 信立泰(成都)生物技术有限公司 一种抗gpc3抗体或抗原结合片段及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU218175A (en) * 1974-09-12 1984-04-30 Schwartzhaupt Kg Process for total or individual determination of lactate dehydrogenase isoenzyme
US5171850A (en) * 1988-08-31 1992-12-15 The Ontario Cancer Institute Intestinal oncofetal gene
JP2946216B2 (ja) 1989-07-12 1999-09-06 武田薬品工業株式会社 新規ハイブリドーマ，モノクローナル抗体および用途
EP0477739A3 (en) * 1990-09-27 1992-12-09 F. Hoffmann-La Roche Ag Glycosyl-phosphatidylinositol-specific phospholipase d
WO1999037764A2 (en) * 1998-01-27 1999-07-29 Vlaams Interuniversitair Instituut Voor Biotechnologie New members of the glypican gene family
WO2000023109A1 (en) * 1998-10-16 2000-04-27 The Regents Of The University Of California Glypicans for the detection and treatment of human carcinoma
AU2002315857B2 (en) * 2001-06-22 2007-07-26 Kaisha, Chugai Seiyaku Kabushiki Cell proliferation inhibitors containing anti-glypican 3 antibody

Also Published As

Publication number Publication date
CN1653336A (zh) 2005-08-10
CA2482881C (en) 2016-11-08
US20050233392A1 (en) 2005-10-20
EP1506406A2 (en) 2005-02-16
RU2004136285A (ru) 2005-10-10
US7883853B2 (en) 2011-02-08
WO2003100429A3 (en) 2004-02-19
PT1506406E (pt) 2009-06-03
ES2324029T3 (es) 2009-07-29
NZ536521A (en) 2006-04-28
RU2319969C2 (ru) 2008-03-20
BRPI0311233B1 (pt) 2019-08-13
AU2003229191B2 (en) 2009-07-30
ATE425461T1 (de) 2009-03-15
ZA200410077B (en) 2005-12-28
MXPA04011132A (es) 2005-08-15
HK1074251A1 (en) 2005-11-04
EP1506406B1 (en) 2009-03-11
JP4455324B2 (ja) 2010-04-21
CA2482881A1 (en) 2003-12-04
DE60326567D1 (de) 2009-04-23
IL164848A0 (en) 2005-12-18
BRPI0311233A2 (pt) 2016-06-28
WO2003100429A2 (en) 2003-12-04
JP2005526979A (ja) 2005-09-08
AU2003229191A1 (en) 2003-12-12
CN100401068C (zh) 2008-07-09

Similar Documents

Publication Publication Date Title
BRPI0311233B8 (pt) métodos in vitro para triagem de um paciente para carcinoma hepatocelular (hcc), e para diagnosticar hcc em um paciente, bem como método e kit para detectar ou determinar o nível de gpc3 em uma amostra
DE602006018578D1 (de) Diagnose- und prognoseverfahren von blasenkrebs.
WO2009019368A3 (fr) Procede de dosage de la liver fatty acid-binding protein, de l'ace et du ca19-9 pour le diagnostic in vitro du cancer colorectal
JP2008522623A5 (pt)
BRPI0412725A (pt) marcadores para detecção de cáncer gástrico
BRPI0707645B8 (pt) métodos in vitro para detecção de câncer em um indivíduo e para avaliação de prognóstico de um indivíduo tendo, ou suspeito de ter, câncer ovariano
EP1810026A4 (en) B7-H1 AND METHOD FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF CANCER
ATE411525T1 (de) Nachweis einer histonmodifikation in zellfreien nukleosomen
GB201120209D0 (en) Methods of monitoring conditions by sequence analysis
WO2008012362A3 (en) New protein isoforms and uses thereof
EP1838867A4 (en) APOLIPOPROTEIN A II ISOFORM AS A BIOMARKER FOR PROSTATE CANCER
DE602006019262D1 (de) QUANTITATIVE ASSAYS FÜR PDGFR-beta- IN KÖRPERFLÜSSIGKEITEN
DK0968421T3 (da) Diagnose af tidlig gastrisk cancer
DE602007007958D1 (de) Antikörper gegen ein epitop auf agr2, assays und hybridome
Zhang et al. Prognosis evaluation in alpha-fetoprotein negative hepatocellular carcinoma after hepatectomy: comparison of five staging systems
RU2011144835A (ru) Способы и композиции на основе белков для диагностики колоректальной аденокарциномы
BRPI0712273A2 (pt) Anticorpos isolados, polipeptídeos imunoglobulinas, anticorpo hepsina, molécula de ácido nucléico, célula hospedeira, linhagem celular, métodos para produzir o anticorpo, para diagnosticar a presença de hepsina, tratar uma doença, para monitorar a doença residual, para detectar o estado da doença, para diagnosticar uma disfunção, composição, arranjo ou chip de proteína e kit
DE60325382D1 (de) Verfahren zur diagnose von gebärmutterhalskrebs
WO2006133923A3 (en) Diagnosis, prognosis and prediction of recurrence of breast cancer
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
BRPI0406265B8 (pt) método para análise por eletroforese capilar, método para pesquisa e tipagem de proteínas monoclonais, método de preparação de anticorpos modificados sobrecarregados negativamente e kit para detecção e tipagem de proteínas monoclonais
WO2003099107A3 (en) Methods and kits for the detection of renal cell carcinoma in a biological fluid of a patient
FR2900936B1 (fr) Procede et methodes de detection de la maladie d'alzheimer
BRPI0607016A2 (pt) marcadores polipeptìdicos para o diagnóstico de cáncer de próstata
ATE406579T1 (de) Verfahren zur diagnose von tumoren

Legal Events

Date Code Title Description
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/05/2003, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2776 DE 19-03-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.